"Bringing A Truly Accurate Blood Test for Alzheimer’s Disease to the Market"
Over the past several years, researchers have come to believe that the best chance to prevent or slow the progression of Alzheimer’s disease (AD) is to begin treatment when patients are in the earliest stages of the disease, which is known to start many years before the onset of cognitive symptoms. A critical issue for researchers focused on developing treatments that could be initiated during the long pre-symptomatic phase of AD is reliable early detection. Current diagnostic methods for detection of AD are expensive and intrusive, with limited ability to identify asymptomatic individuals. There is a strong demand for a quick, easy and cost effective assay for the early detection of AD.
NanoSomiX , a molecular diagnostics laboratory, has developed a breakthrough technology capable of measuring the most critical known AD biomarkers in blood. Measurement of these biomarkers opens the door to early detection of AD as well as the potential for real time monitoring of the disease. The Company’s proprietary approach measures these key biomarkers by identifying, enriching and analyzing neural derived exosomes from blood. Exosomes are tiny membrane-encased vesicles which contain biomarkers known to be important in measuring neurologic status. Our first assay, NSX Direct™, uses neural derived exosomes to detect elevated levels of two key proteins involved in the pathogenesis of AD (p-tau and Abeta). These markers are well known to correlate with disease and have been shown to increase up to ten years before the onset of cognitive impairment. Our technology is the only approach that can measure both biomarkers in blood, giving our assay the potential to be the most practical and cost effective AD diagnostic methodology available.
NanoSomiX is now offering NSX Direct™ for Research Use Only (RUO) with plans to transition to a Laboratory Developed Test (LDT) with additional validation studies. Our assays are performed in a federally regulated clinical (CLIA) laboratory. In the near future, we will be introducing new assay panels that include additional AD-related biomarkers. Moving forward, we plan to expand our technology platform to include a vast array of biomarkers focused on neurodegenerative, neuroinflammatory and neurotraumatic diseases.
In The News
- Alzheimer’s Diagnostic Tests Inch Forward, but Treatments Are Still Lacking - Scientific American
- Alzheimer's Test Detects Disease Decade Ahead of Onset - Bloomberg News
- New Test May Predict Alzheimer’s 10 Years Before Diagnosis - Time.com